Neuphoria Therapeutics Inc. (NEUP): Cash & Equivalents
$19.87M
As of 2026-06-30
+18.0%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $19.87M | +39.8% | 2026-09-18, Balance as of period end |
| 2025-06-30 | $14.21M | +12.7% | 2026-09-18, Balance as of period end |
| 2024-06-30 | $12.61M | +4.2% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $12.10M | n/a | 2024-09-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $28.18M | +55.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.51M | -9.0% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗